{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:31:13Z","timestamp":1793428273839,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.talanta.2026.130717","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:43:24Z","timestamp":1790783004000},"page":"130717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["Glycopeptide-based classification of erythropoietin biopharmaceuticals by microseparation techniques coupled to mass spectrometry and multivariate analysis"],"prefix":"10.1016","volume":"313","author":[{"given":"Helena","family":"Tejero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3402-1777","authenticated-orcid":false,"given":"Montserrat","family":"Mancera-Arteu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-0450","authenticated-orcid":false,"given":"Laura","family":"Pont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Benavente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.talanta.2026.130717_bib1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000356193","article-title":"Physiology and pharmacology of erythropoietin","volume":"40","author":"Jelkmann","year":"2013","journal-title":"Transfus. Med. Hemotherapy"},{"key":"10.1016\/j.talanta.2026.130717_bib2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.V77.3.419.419","article-title":"Erythropoietin","volume":"77","author":"Krantz","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.talanta.2026.130717_bib3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nurt.2008.10.041","article-title":"Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system","volume":"6","author":"Sir\u00e9n","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.talanta.2026.130717_bib4","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.4103\/1673-5374.215240","article-title":"Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor","volume":"12","author":"Hern\u00e1ndez","year":"2017","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.talanta.2026.130717_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.841538","article-title":"Editorial: Erythropoietin and its analogues as therapeutics for neurological diseases","volume":"13","author":"Brines","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.talanta.2026.130717_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17091190","article-title":"Personalized therapeutic advances in erythropoietin signaling: from anemia management to extensive clinical applications","volume":"17","author":"Creang\u0103","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.talanta.2026.130717_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.1098313","article-title":"Derivatives of erythropoietin that are tissue protective but not erythropoietic","volume":"305","author":"Leist","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.talanta.2026.130717_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.381","article-title":"The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage","volume":"8","author":"Yoo","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.talanta.2026.130717_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.728725","article-title":"Erythropoietin and non-erythropoietic derivatives in cognition","volume":"12","author":"Newton","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.talanta.2026.130717_bib10","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4103\/1673-5374.255968","article-title":"Neuroprotective effect of Neuro-EPO in neurodegenerative diseases: \u201calea jacta est,\u201d","volume":"14","author":"Rama","year":"2019","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.talanta.2026.130717_bib11","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/dta.2924","article-title":"Detection of a nonerythropoietic erythropoietin, Neuro-EPO, in blood after intranasal administration in rat","volume":"12","author":"Martin","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.talanta.2026.130717_bib12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1100\/tsw.2009.103","article-title":"The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans","volume":"9","author":"Rodr\u00edguez","year":"2009","journal-title":"Sci. World J."},{"key":"10.1016\/j.talanta.2026.130717_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-023-01356-w","article-title":"NeuroEPO plus (NeuralCIM\u00ae) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial","volume":"15","author":"Sosa","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.talanta.2026.130717_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aca.2019.08.044","article-title":"Glycosylation of biosimilars: recent advances in analytical characterization and clinical implications","volume":"1089","author":"Duivelshof","year":"2019","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.talanta.2026.130717_bib15","first-page":"3199","article-title":"Erythropoietin concentrated solution","year":"2005","journal-title":"European Pharmacopoeia"},{"key":"10.1016\/j.talanta.2026.130717_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114686","article-title":"Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis","volume":"213","author":"Garc\u00eda-Artalejo","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2026.130717_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.aca.2011.10.028","article-title":"Analysis of recombinant human erythropoietin glycopeptides by capillary electrophoresis electrospray-time of flight-mass spectrometry","volume":"709","author":"Gim\u00e9nez","year":"2012","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.talanta.2026.130717_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2019.120563","article-title":"Analysis of glycopeptide biomarkers by on-line TiO2 solid-phase extraction capillary electrophoresis-mass spectrometry","volume":"209","author":"Mancera-Arteu","year":"2020","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2026.130717_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1021\/acs.jproteome.2c00569","article-title":"Sensitive analysis of recombinant human erythropoietin glycopeptides by on-line phenylboronic acid solid-phase extraction capillary electrophoresis mass spectrometry","volume":"22","author":"Mancera-Arteu","year":"2023","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.talanta.2026.130717_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2024.110386","article-title":"Microseparation techniques coupled to mass spectrometry for a sensitive and unequivocal identification of glycopeptides","volume":"200","author":"Pont","year":"2024","journal-title":"Microchem. J."},{"key":"10.1016\/j.talanta.2026.130717_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.talanta.2016.07.055","article-title":"Classification of congenital disorders of glycosylation based on analysis of transferrin glycopeptides by capillary liquid chromatography-mass spectrometry","volume":"160","author":"Barroso","year":"2016","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2026.130717_bib22","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1021\/acs.jproteome.6b00429","article-title":"HILIC and ERLIC enrichment of glycopeptides derived from breast and brain cancer cells","volume":"15","author":"Zacharias","year":"2016","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.talanta.2026.130717_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1389-7","article-title":"IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis","volume":"19","author":"Lundstr\u00f6m","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.talanta.2026.130717_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2019.103616","article-title":"Comprehensive analysis of human IgG Fc N-glycopeptides and construction of a screening model for colorectal cancer","volume":"213","author":"Zou","year":"2020","journal-title":"J. Proteomics"},{"key":"10.1016\/j.talanta.2026.130717_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/jimd.12557","article-title":"N-glycoproteomics reveals distinct glycosylation alterations in NGLY1-deficient patient-derived dermal fibroblasts","volume":"46","author":"Budhraja","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.talanta.2026.130717_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12885-025-13616-z","article-title":"Site-specific immunoglobulin G N-glycosylation is associated with gastric cancer progression","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.talanta.2026.130717_bib27","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1021\/acs.jproteome.5b01029","article-title":"Approaches to sample size determination for multivariate data: applications to PCA and PLS-DA of omics data","volume":"15","author":"Saccenti","year":"2016","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.talanta.2026.130717_bib28","series-title":"Agilent Technologies, Waldbronn, Germany","first-page":"60","article-title":"High performance capillary electrophoresis","author":"Lauer","year":"2014"},{"key":"10.1016\/j.talanta.2026.130717_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jprot.2019.01.006","article-title":"Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma","volume":"195","author":"Mancera-Arteu","year":"2019","journal-title":"J. Proteomics"},{"key":"10.1016\/j.talanta.2026.130717_bib30","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/acs.jproteome.0c00016","article-title":"Alterations in the glycan profile of mouse transferrin: new insights in collagen-induced arthritis","volume":"19","author":"Mancera-Arteu","year":"2020","journal-title":"J. Proteome Res."}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914026013731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914026013731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:38:36Z","timestamp":1793425116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914026013731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":30,"alternative-id":["S0039914026013731"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2026.130717","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycopeptide-based classification of erythropoietin biopharmaceuticals by microseparation techniques coupled to mass spectrometry and multivariate analysis","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2026.130717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"130717"}}